GLP-1semaglutidetirzepatidealcohol use disorderreview

Review finds semaglutide cuts alcohol craving but no approval for AUD

Randomized trials reduced drinks per drinking day even in non-treatment-seeking drinkers, with effects strongest in people with comorbid obesity or metabolic disease.

By Maren Holt · Senior Reporter, GLP-1

Oct 9 20:00 ETSource: Addictive behaviors

The wire

01A review in Addictive Behaviors collected randomized trials and cohort data showing once-weekly semaglutide reduced alcohol cravings and drinks per drinking day, with fewer AUD-related hospitalizations among users.
02Tirzepatide data showed lower binge-drinking odds and AUDIT scores, relevant to clinicians already fielding off-label requests for incretins in alcohol use disorder.
03Authors stress no GLP-1 receptor agonist is FDA-approved for AUD; evidence is limited by small samples, short follow-up, self-reported outcomes and weight-loss confounding.

From the source

Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms
Addictive behaviors · 2026 Oct 10 · Nittur A, Belzar A, Rai C et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42880142/